New Drug to Reduce Fracture Risk in Postmenopausal Osteoporosis

Postmenopausal women with osteoporosis can reduce their risk of spine fracture when treated with romosozumab drug. The study results were presented at the Annual European Congress of Rheumatology (EULAR) 2017 press conference. The research team had found that treatment for 12 months with the new class of drug could actually be associated with rapid and large reductions in the risk of vertebral fracture when compared to placebo.

Related Links